---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097001"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:14:53.982241+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M

## Summary
- ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.
- CNSide diagnostic met primary endpoint: helped clinical decisions in >90% of cases; tumor cell detection 80% vs 29% cytology.
- Received $3.3M CPRIT grant in June 2024 for Rhenium (186Re) Obisbemeda development.
- Cash $8.4M at June 30; H1 net loss $6.2M ($1.15/share) vs $6.3M ($2.60/share) year ago.
- Upcoming: complete ReSPECT-LM Phase 1 single-dose, initiate multiple-dose Phase 1, and IND for pediatric trial.

## SEC filing metadata
- accession: 0000950170-24-097001
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/0000950170-24-097001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/pstv-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097001
- JSON: https://secwatch.observer/filing/0000950170-24-097001.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.